{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:19:13Z","timestamp":1789647553873,"version":"4.0.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The clinical impact of different polymer technologies in newer-generation drug-eluting stents (DESs) for patients with acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) remains poorly understood. We investigated the efficacy and safety of durable polymer DESs (DP-DESs) compared with biodegradable polymer DESs (BP-DESs). A total of 620 patients who underwent percutaneous coronary intervention with newer-generation DESs for AMI complicated by CS was divided into two groups based on polymer technology: the DP-DES group (n\u2009=\u2009374) and the BP-DES group (n\u2009=\u2009246). The primary outcome was target vessel failure (TVF) during a 12-month follow-up, defined as a composite of cardiac death, myocardial infarction, or target vessel revascularization. Both the DP-DES and BP-DES groups exhibited low stent thrombosis rates (1.3% vs. 1.6%, p\u2009=\u20090.660). The risk of TVF did not significantly differ between the two groups (34.2% vs. 28.5%, hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.69\u20131.29,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.721). This finding remained consistent after adjustment with inverse probability of treatment weighting (28.1% vs. 25.1%, HR 0.98, 95% CI 0.77\u20131.27,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.899). In AMI patients complicated by CS, the risk of a composite of cardiac death, myocardial infarction, or target vessel revascularization was not significantly different between those treated with DP-DESs and those treated with BP-DESs.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial registration:<\/jats:bold>\n                    RESCUE registry,\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02985008\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02985008<\/jats:ext-link>\n                    , NCT02985008.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-56925-2","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T10:01:48Z","timestamp":1710496908000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of durable versus biodegradable polymer drug-eluting stents in patients with acute myocardial infarction complicated by cardiogenic shock"],"prefix":"10.1038","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct02985008","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Woo Jin","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ik Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hyeon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Hong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Bin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-Yong","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hyuk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Cheol","family":"Gwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul-Min","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol Woong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Joong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang-Whan","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Uk","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ok","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Don","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Hoon","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"56925_CR1","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacc.2010.05.066","volume":"57","author":"G Nakazawa","year":"2011","unstructured":"Nakazawa, G. et al. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. J. Am. Coll. Cardiol. 57, 390\u2013398. https:\/\/doi.org\/10.1016\/j.jacc.2010.05.066 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"56925_CR2","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1161\/CIRCULATIONAHA.107.762047","volume":"118","author":"G Nakazawa","year":"2008","unstructured":"Nakazawa, G. et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: An autopsy study. Circulation 118, 1138\u20131145. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.762047 (2008).","journal-title":"Circulation"},{"key":"56925_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacc.2014.04.022","volume":"64","author":"G Sarno","year":"2014","unstructured":"Sarno, G. et al. Stent thrombosis in new-generation drug-eluting stents in patients with STEMI undergoing primary PCI: A report from SCAAR. J. Am. Coll. Cardiol. 64, 16\u201324. https:\/\/doi.org\/10.1016\/j.jacc.2014.04.022 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"56925_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41569-019-0234-x","volume":"17","author":"S Torii","year":"2020","unstructured":"Torii, S. et al. Drug-eluting coronary stents: Insights from preclinical and pathology studies. Nat. Rev. Cardiol. 17, 37\u201351. https:\/\/doi.org\/10.1038\/s41569-019-0234-x (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"56925_CR5","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1093\/eurheartj\/ehz244","volume":"40","author":"S Buccheri","year":"2019","unstructured":"Buccheri, S. et al. Clinical and angiographic outcomes of bioabsorbable vs. permanent polymer drug-eluting stents in Sweden: A report from the Swedish Coronary and Angioplasty Registry (SCAAR). Eur. Heart J. 40, 2607\u20132615. https:\/\/doi.org\/10.1093\/eurheartj\/ehz244 (2019).","journal-title":"Eur. Heart J."},{"key":"56925_CR6","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1161\/CIRCULATIONAHA.120.051700","volume":"143","author":"HS Kim","year":"2021","unstructured":"Kim, H. S. et al. Durable polymer versus biodegradable polymer drug-eluting stents after percutaneous coronary intervention in patients with acute coronary syndrome: The HOST-REDUCE-POLYTECH-ACS trial. Circulation 143, 1081\u20131091. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051700 (2021).","journal-title":"Circulation"},{"key":"56925_CR7","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1710261","volume":"377","author":"H Thiele","year":"2017","unstructured":"Thiele, H. et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N. Engl. J. Med. 377, 2419\u20132432. https:\/\/doi.org\/10.1056\/NEJMoa1710261 (2017).","journal-title":"N. Engl. J. Med."},{"key":"56925_CR8","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1161\/CIR.0000000000000525","volume":"136","author":"S van Diepen","year":"2017","unstructured":"van Diepen, S. et al. Contemporary management of cardiogenic shock: A scientific statement from the American Heart Association. Circulation 136, e232\u2013e268. https:\/\/doi.org\/10.1161\/CIR.0000000000000525 (2017).","journal-title":"Circulation"},{"key":"56925_CR9","doi-asserted-by":"publisher","first-page":"e008141","DOI":"10.1161\/CIRCHEARTFAILURE.120.008141","volume":"14","author":"JH Yang","year":"2021","unstructured":"Yang, J. H. et al. Clinical characteristics and predictors of in-hospital mortality in patients with cardiogenic shock: Results from the RESCUE registry. Circ. Heart Fail. 14, e008141. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.008141 (2021).","journal-title":"Circ. Heart Fail."},{"key":"56925_CR10","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/j.jacc.2010.02.008","volume":"55","author":"YB Song","year":"2010","unstructured":"Song, Y. B. et al. Sirolimus- versus paclitaxel-eluting stents for the treatment of coronary bifurcations results: From the COBIS (Coronary Bifurcation Stenting) registry. J. Am. Coll. Cardiol. 55, 1743\u20131750. https:\/\/doi.org\/10.1016\/j.jacc.2010.02.008 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"56925_CR11","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine, G. N. et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 68, 1082\u20131115. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.513 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"56925_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli, M. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 39, 213\u2013260. https:\/\/doi.org\/10.1093\/eurheartj\/ehx419 (2018).","journal-title":"Eur. Heart J."},{"key":"56925_CR13","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip, D. E. et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 115, 2344\u20132351. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.685313 (2007).","journal-title":"Circulation"},{"key":"56925_CR14","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","volume":"123","author":"K Kolandaivelu","year":"2011","unstructured":"Kolandaivelu, K. et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 123, 1400\u20131409. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.003210 (2011).","journal-title":"Circulation"},{"key":"56925_CR15","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa0910496","volume":"362","author":"GW Stone","year":"2010","unstructured":"Stone, G. W. et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N. Engl. J. Med. 362, 1663\u20131674. https:\/\/doi.org\/10.1056\/NEJMoa0910496 (2010).","journal-title":"N. Engl. J. Med."},{"key":"56925_CR16","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jcin.2010.07.008","volume":"3","author":"MB Leon","year":"2010","unstructured":"Leon, M. B. et al. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease) trial. JACC Cardiovasc. Interv. 3, 1043\u20131050. https:\/\/doi.org\/10.1016\/j.jcin.2010.07.008 (2010).","journal-title":"JACC Cardiovasc. Interv."},{"key":"56925_CR17","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jcin.2020.12.011","volume":"14","author":"T Pilgrim","year":"2021","unstructured":"Pilgrim, T. et al. Biodegradable- versus durable-polymer drug-eluting stents for STEMI: Final 2-year outcomes of the BIOSTEMI trial. JACC Cardiovasc. Interv. 14, 639\u2013648. https:\/\/doi.org\/10.1016\/j.jcin.2020.12.011 (2021).","journal-title":"JACC Cardiovasc. Interv."},{"key":"56925_CR18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.115.003610","author":"LO Jensen","year":"2016","unstructured":"Jensen, L. O. et al. Randomized comparison of a biodegradable polymer ultrathin strut sirolimus-eluting stent with a biodegradable polymer biolimus-eluting stent in patients treated with percutaneous coronary intervention: The SORT OUT VII trial. Circ. Cardiovasc. Interv. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.115.003610 (2016).","journal-title":"Circ. Cardiovasc. Interv."},{"key":"56925_CR19","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/S0140-6736(18)32001-4","volume":"392","author":"C von Birgelen","year":"2018","unstructured":"von Birgelen, C. et al. Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): An international, single-blind, randomised non-inferiority trial. Lancet 392, 1235\u20131245. https:\/\/doi.org\/10.1016\/S0140-6736(18)32001-4 (2018).","journal-title":"Lancet"},{"key":"56925_CR20","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/S0140-6736(19)31877-X","volume":"394","author":"JF Iglesias","year":"2019","unstructured":"Iglesias, J. F. et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): A single-blind, prospective, randomised superiority trial. Lancet 394, 1243\u20131253. https:\/\/doi.org\/10.1016\/S0140-6736(19)31877-X (2019).","journal-title":"Lancet"},{"key":"56925_CR21","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.jcin.2020.02.019","volume":"13","author":"DE Kandzari","year":"2020","unstructured":"Kandzari, D. E. et al. Ultrathin bioresorbable-polymer sirolimus-eluting stents versus thin durable-polymer everolimus-eluting stents for coronary revascularization: 3-year outcomes from the randomized BIOFLOW V trial. JACC Cardiovasc. Interv. 13, 1343\u20131353. https:\/\/doi.org\/10.1016\/j.jcin.2020.02.019 (2020).","journal-title":"JACC Cardiovasc. Interv."},{"key":"56925_CR22","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1056\/NEJMoa1808788","volume":"379","author":"H Thiele","year":"2018","unstructured":"Thiele, H. et al. One-year outcomes after PCI strategies in cardiogenic shock. N. Engl. J. Med. 379, 1699\u20131710. https:\/\/doi.org\/10.1056\/NEJMoa1808788 (2018).","journal-title":"N. Engl. J. Med."},{"key":"56925_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.rec.2018.01.003","volume":"72","author":"SJ Na","year":"2019","unstructured":"Na, S. J. et al. Vasoactive inotropic score as a predictor of mortality in adult patients with cardiogenic shock: Medical therapy versus ECMO. Rev. Esp. Cardiol. (Engl. Ed.) 72, 40\u201347. https:\/\/doi.org\/10.1016\/j.rec.2018.01.003 (2019).","journal-title":"Rev. Esp. Cardiol. (Engl. Ed.)"},{"key":"56925_CR24","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(23)02197-9","volume":"402","author":"JF Iglesias","year":"2023","unstructured":"Iglesias, J. F. et al. Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial. Lancet 402, 1979\u20131990. https:\/\/doi.org\/10.1016\/S0140-6736(23)02197-9 (2023).","journal-title":"Lancet"},{"key":"56925_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jcin.2019.08.020","volume":"13","author":"JC Choe","year":"2020","unstructured":"Choe, J. C. et al. Long-term outcomes of biodegradable versus second-generation durable polymer drug-eluting stent implantations for myocardial infarction. JACC Cardiovasc. Interv. 13, 97\u2013111. https:\/\/doi.org\/10.1016\/j.jcin.2019.08.020 (2020).","journal-title":"JACC Cardiovasc. Interv."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-56925-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-56925-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-56925-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T10:16:33Z","timestamp":1710497793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-56925-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["56925"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-56925-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]},"assertion":[{"value":"31 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6301"}}